Navigation Links
Obesity Significantly Increases Side Effects of Stereotactic Body Radiation Therapy in Lung Cancer Patients
Date:11/2/2009

CHICAGO, Nov. 2 /PRNewswire-USNewswire/ -- Obesity, not the amount of radiation given, is the greatest factor in whether early-stage lung cancer patients develop chest wall pain after receiving stereotactic body radiation therapy to the chest wall, with obese patients being more than twice as likely to develop chronic pain compared to those who have less body weight, according to a first-of-its-kind study presented Tuesday, November 3, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Researchers studied other factors associated with obesity, such as diabetes, to find out why obesity in patients increased chest wall pain. Findings show that obese patients who are diabetic are over three times more likely to develop chest wall pain after receiving stereotactic body radiation therapy to the chest wall, compared to patients who do not have diabetes.

"The study shows that physiological factors, such as obesity and diabetes, can play a major role in the development of radiation-related toxicity," James Welsh, M.D., lead author of the study and a radiation oncologist at the M.D. Anderson Cancer Center in Houston said. "This is a surprising finding, since most side effects of radiation treatment are based on the amount of normal tissue that is treated and the volume of the dose."

The main purpose of the study was to find out what the highest amount of radiation that could be delivered to the chest wall using a specialized type of radiation treatment called stereotactic body radiation therapy (SBRT) without patients developing the late side effects of pain and skin reactions. The study shows that patients who receive a high dose of radiation to cancer close to the chest wall (in the amount of 35 gray (Gy)) have an increased chance of having pain and skin reactions, compared to those who have a lower radiation dose.

SBRT is a specialized type of external beam radiation therapy that pinpoints high doses of radiation directly on the cancer in a shorter amount of time than traditional treatments. Cancer centers often call the treatments by the brand names of the manufacturers, including Axesse, CyberKnife, Gamma Knife, Novalis, Primatom, Synergy, X-Knife, TomoTherapy and Trilogy. Treatment is typically delivered in 1 to 2 weeks, instead of a period of 6 to 8 weeks.

"SBRT is now being investigated as a replacement to surgery for early-stage lung cancer. If this non-invasive technique is to replace surgery, not only does it need to be effective, but also safe," Dr. Welsh said. "Since this study shows that a 35Gy dose of radiation, obesity, and diabetes increase the risk of developing late negative side effects after high dose radiation, then we can take steps to reduce these side effects."

The study involved 265 patients with tumors within less than 2.5 centimeters of the chest wall, who were treated with SBRT between August 2004 and August 2008. Of these patients, 39 percent developed skin toxicity, while six percent developed acute pain and 22 percent developed chronic pain. In patients who are considered obese, diabetes mellitus was found to be a significant contributing factor in the development of chest pain.

For more information on cancer and stereotactic radiation therapy, visit www.rtanswers.org.

The abstract, "Skin Toxicity And Pain In Patients Treated With Stereotactic Body Radiotherapy," will be presented at a scientific session at 3:20 p.m. on Tuesday, November 3, 2009. To speak to the lead author of the study, James Welsh, M.D., please call Beth Bukata or Nicole Napoli November 1-4, 2009, in the ASTRO Press Room at McCormick Place West at 312-791-7005 or 312-791-7006. You may also e-mail them at bethb@astro.org or nicolen@astro.org.

SOURCE American Society for Radiation Oncology


'/>"/>
SOURCE American Society for Radiation Oncology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
2. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
3. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
4. A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
5. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
6. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
7. Is Obesity an Oral Bacterial Disease?
8. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
9. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
10. Complications and Costs for Obesity Surgery Declining
11. Obesity Associated With Higher Risk for Urinary Tract Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... 2017  Radium Medical Aesthetics, a leading medical aesthetic clinic in ... by effectively addressing several skin conditions from the inside. ... and more fragile. The skin becomes more transparent due to the ... harmful UV rays from the sun contributes to aging skin, causing ... ...
(Date:7/26/2017)... The Galien Foundation announced today the 2017 11 ... Award Nominees. Counted among the global health innovation industry,s most ... technology product achievement that improves the human condition. ... be U.S. Food and Drug Administration (FDA) approved for market ... impact human health. Sales data are not considered by the ...
Breaking Medicine Technology:
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... says will lift the veil on false teachings pertaining to the mother of the Savior ... teach, you see a far different picture of the role of this historical woman. ...
(Date:8/18/2017)... ... 2017 , ... “Our Mountains to Climb: A Journey of Love and Faith ... together through the faith they shared to overcome struggles in life. “Our Mountains to ... author, Barbara J. Corcoran, a retired teacher and happily married since 1999; the author’s ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Depressed: Super Heroes of the ... to reflect upon the stories and the relevance these tales may have on the ... Jessica Linhart, a former special education teacher, Jessica spends much of her time enjoying ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Steve the Snake”: ... “Steve the Snake” is the creation of published author, Harold Flash Haskins Jr., a ... a Department of Defense police officer. , “I write moral-based short stories for children ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... announces that it will feature the National Council for Therapeutic Recreation Certification (NCTRC), ... information. , Established in 1981, NCTRC is a non-profit, international organization dedicated to ...
Breaking Medicine News(10 mins):